희귀 혈우병 인자 시장

Global Rare Hemophilia Factors Market to Reach US$371.4 Million by 2032

The global market for Rare Hemophilia Factors estimated at US$265.3 Million in the year 2025, is expected to reach US$371.4 Million by 2032, growing at a CAGR of 4.9% over the analysis period 2025-2032. Fresh Frozen Plasma, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$178.2 Million by the end of the analysis period. Growth in the Factor Concentrates segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$77.6 Million While China is Forecast to Grow at 4.8% CAGR

The Rare Hemophilia Factors market in the U.S. is estimated at US$77.6 Million in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$66.5 Million by the year 2032 trailing a CAGR of 4.8% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Rare Hemophilia Factors: Key Elements in Blood Clotting Disorders

What Are Rare Hemophilia Factors and Why Are They Important?

Rare hemophilia factors refer to less common clotting factor deficiencies involved in blood coagulation. While hemophilia A and B, caused by deficiencies in clotting factors VIII and IX respectively, are the most well-known forms, rare hemophilia factors involve deficiencies in factors I, II, V, VII, X, XI, and XIII. These rare bleeding disorders are collectively termed “rare factor deficiencies” or “rare coagulation disorders” and are less common than hemophilia A and B, often affecting only a small fraction of the global population. Despite their rarity, these deficiencies pose significant health challenges, as they disrupt normal blood clotting and increase the risk of severe bleeding events.

Each clotting factor plays a specific role in the coagulation cascade, a series of reactions that ultimately form a blood clot to stop bleeding. When one of these factors is deficient, the clotting process is interrupted, leading to prolonged bleeding following injuries, surgeries, or even spontaneously. Rare hemophilia factors vary in their severity, with some deficiencies causing life-threatening bleeding, while others result in milder symptoms. Because these disorders are so uncommon, they are often underdiagnosed or misdiagnosed, making awareness and specialized treatment essential for proper management and improved quality of life for affected individuals.

How Are Rare Hemophilia Factors Diagnosed and Treated?

Diagnosis of rare hemophilia factors generally involves a combination of blood tests, including coagulation tests, genetic testing, and specific clotting factor assays to identify the precise factor deficiency. Patients typically present with unexplained or prolonged bleeding, which prompts physicians to conduct these tests. Genetic testing is especially useful in confirming a diagnosis, as most rare hemophilia factors are inherited in an autosomal recessive pattern, meaning both parents must carry a defective gene for a child to exhibit symptoms. This type of testing also helps in understanding the inheritance pattern, which is crucial for family counseling and future planning.

Treatment for rare factor deficiencies typically involves factor replacement therapy, which replaces the missing or deficient clotting factor. This therapy can be administered as needed (on-demand) to control bleeding episodes or prophylactically to prevent bleeding, particularly in severe cases. Plasma-derived concentrates are often used for rare factor deficiencies, as synthetic (recombinant) versions are typically unavailable for many of these factors due to their rarity. For some deficiencies, such as Factor VII or Factor XIII, recombinant therapies are available and offer more consistent dosing with a lower risk of infection. Antifibrinolytic medications, like tranexamic acid, may also be used alongside replacement therapy to prevent excessive bleeding, especially for procedures or surgeries. In cases where genetic testing has identified the mutation, gene therapy is being explored as a potential treatment, offering a promising avenue for long-term management of rare factor deficiencies.

What Is Driving the Growth in Research and Treatment of Rare Hemophilia Factors?

The growth in research and treatment options for rare hemophilia factors is driven by advancements in genetic testing, increased awareness of rare bleeding disorders, and the development of innovative therapies. Improvements in genetic sequencing and diagnostic tools have made it easier to accurately diagnose rare factor deficiencies, enabling timely intervention and personalized treatment plans. Increased awareness among healthcare providers and patients has also led to better identification and understanding of these conditions, reducing the prevalence of misdiagnosis and facilitating more effective care.

The development of gene therapy and recombinant factor products is also a significant driver in the field. Gene therapy holds promise for providing long-term solutions for patients with factor deficiencies by addressing the root genetic cause, potentially eliminating the need for frequent factor replacement therapy. Clinical trials in gene therapy for hemophilia A and B have shown promising results, and research efforts are expanding to include rare factor deficiencies. Additionally, recombinant factor therapies and advances in plasma-derived products have improved safety and efficacy for patients requiring replacement therapy. Together, these advancements highlight the growing commitment to improving the lives of individuals with rare hemophilia factors, providing hope for more sustainable and effective treatments in the near future.

SCOPE OF STUDY:

The report analyzes the Rare Hemophilia Factors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate, Other Treatments)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

SELECT PLAYERS -

• Baxalta
• Bayer healthcare
• Bio Products Laboratory Ltd
• Biogen
• CSL Behring
• Novo Nordisk
• Pfizer, Inc.
• Shire
• Takeda Pharmaceutical Co. Ltd.

WHAT SETS THIS REPORT APART FROM OTHERS?

Validated Sources - Human-curated validation and ranking of original source content, not AI LLM-generated synthetic content which dominates the internet today and has become a quick fix for most published research reports these days. Unlike most other published sources, our customers have access to full-stack source content. Our report draws from "real intelligence" balancing the power of AI against the risks of synthetically generated content and resulting biases. Customers have access to the source feeds.

Domain Expert Insights - Domain expert insights curated from enterprise, industry, academia, and government, consolidated from multilingual multimedia formats of text, voice, and images comprise a significant resource. Customers can request access to the pool of domain experts we track for this research project. We track 11,596 domain experts and their insights as part of this research project. Our customers may access our online tracker.

Annual subscription - Recommended for maximum value for your research dollar. Provides one additional full update during the 12 months and access to our research portal and interactive 10-user peer-to-peer collaboration drawing from our entire stack of validated project data which is updated on a weekly basis. Platform also enables adding enterprise data or third-party licensed content to build bespoke versions. Includes competitor tracking of up to 50 companies featured in the report.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Global Economic Update
  • Rare Hemophilia Factors - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Hemophilia and Other Bleeding Disorders Drives Demand for Rare Hemophilia Factor Therapies
  • Advancements in Gene Therapy for Hemophilia Expand Opportunities for Rare Hemophilia Factor Treatments
  • Growing Awareness and Early Diagnosis of Hemophilia Spur Demand for Specialized Factor Replacement Therapies
  • Increasing Focus on Personalized Medicine Boosts Adoption of Rare Hemophilia Factor Products for Targeted Care
  • Expansion of Recombinant Factor Therapies Drives Growth in Rare Hemophilia Factor Market
  • Rising Demand for Prophylactic Treatments to Prevent Bleeding Episodes Expands Applications for Hemophilia Factors
  • Technological Innovations in Factor Concentrates Improve Stability and Efficacy of Rare Hemophilia Treatments
  • Increasing Adoption of Long-Acting Factor Therapies Reduces Treatment Burden for Hemophilia Patients
  • Collaborations Between Pharmaceutical Companies and Research Institutes Drive Innovation in Rare Hemophilia Factor Solutions
  • Growing Use of Plasma-Derived and Recombinant Factors Supports Market Expansion for Hemophilia Treatments
  • Rising Demand for Home Infusion Therapies Enhances Accessibility and Convenience for Hemophilia Patients
  • Expansion of Hemophilia Treatment Centers Improves Access to Rare Hemophilia Factors in Emerging Markets
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Rare Hemophilia Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • TABLE 2: World Historic Review for Rare Hemophilia Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 3: World 13-Year Perspective for Rare Hemophilia Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020, 2026 & 2032
  • TABLE 4: World Recent Past, Current & Future Analysis for Fresh Frozen Plasma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • TABLE 5: World Historic Review for Fresh Frozen Plasma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 6: World 13-Year Perspective for Fresh Frozen Plasma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • TABLE 7: World Recent Past, Current & Future Analysis for Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • TABLE 8: World Historic Review for Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 9: World 13-Year Perspective for Factor Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • TABLE 10: World Recent Past, Current & Future Analysis for Cryoprecipitate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • TABLE 11: World Historic Review for Cryoprecipitate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 12: World 13-Year Perspective for Cryoprecipitate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • TABLE 13: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • TABLE 14: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 15: World 13-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020, 2026 & 2032
  • TABLE 16: World Rare Hemophilia Factors Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032

III. MARKET ANALYSIS

• UNITED STATES
  • Rare Hemophilia Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
  • TABLE 17: USA Recent Past, Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 18: USA Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 19: USA 13-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2020, 2026 & 2032
• CANADA
  • TABLE 20: Canada Recent Past, Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 21: Canada Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 22: Canada 13-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2020, 2026 & 2032
• JAPAN
  • Rare Hemophilia Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
  • TABLE 23: Japan Recent Past, Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 24: Japan Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 25: Japan 13-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2020, 2026 & 2032
• CHINA
  • Rare Hemophilia Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
  • TABLE 26: China Recent Past, Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 27: China Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 28: China 13-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2020, 2026 & 2032
• EUROPE
  • Rare Hemophilia Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Rare Hemophilia Factors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
  • TABLE 30: Europe Historic Review for Rare Hemophilia Factors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 31: Europe 13-Year Perspective for Rare Hemophilia Factors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020, 2026 & 2032
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 33: Europe Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 34: Europe 13-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2020, 2026 & 2032
• FRANCE
  • Rare Hemophilia Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
  • TABLE 35: France Recent Past, Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 36: France Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 37: France 13-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2020, 2026 & 2032
• GERMANY
  • Rare Hemophilia Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
  • TABLE 38: Germany Recent Past, Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 39: Germany Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 40: Germany 13-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2020, 2026 & 2032
• ITALY
  • TABLE 41: Italy Recent Past, Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 42: Italy Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 43: Italy 13-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2020, 2026 & 2032
• UNITED KINGDOM
  • Rare Hemophilia Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
  • TABLE 44: UK Recent Past, Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 45: UK Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 46: UK 13-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2020, 2026 & 2032
• REST OF EUROPE
  • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 48: Rest of Europe Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 49: Rest of Europe 13-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2020, 2026 & 2032
• ASIA-PACIFIC
  • Rare Hemophilia Factors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
  • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 51: Asia-Pacific Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 52: Asia-Pacific 13-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2020, 2026 & 2032
• REST OF WORLD
  • TABLE 53: Rest of World Recent Past, Current & Future Analysis for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
  • TABLE 54: Rest of World Historic Review for Rare Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
  • TABLE 55: Rest of World 13-Year Perspective for Rare Hemophilia Factors by Treatment - Percentage Breakdown of Value Sales for Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other Treatments for the Years 2020, 2026 & 2032

IV. COMPETITION